Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic…
108,641$
0,80%
Echtzeit-Aktienkurs Blueprint Medicines Corp.
Bid:
Ask:
Nachrichten zur Blueprint Medicines Corp. Aktie
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
-- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/…
Blueprint Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 4, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
Blueprint Medicines (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance…
Form 10-Q Blueprint Medicines Corp For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines GAAP EPS of -$2.23 beats by $0.28, revenue of $65.97M beats by $22.09M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined…
Insiderhandel: PRESIDENT, R & D verkauft Aktien von Blueprint Medicines im Wert von 234.002$
Namouni, Fouad - Vorstand - Tag der Transaktion: 2022-10-04...…
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to…